<SEC-DOCUMENT>0001628280-23-020484.txt : 20230601
<SEC-HEADER>0001628280-23-020484.hdr.sgml : 20230601
<ACCEPTANCE-DATETIME>20230601152232
ACCESSION NUMBER:		0001628280-23-020484
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230601
FILED AS OF DATE:		20230601
DATE AS OF CHANGE:		20230601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		23984406

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk06x01x2023.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i64ce6a54e891413e857a58f121d51847_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the month of June, 2023.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 1, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="cybnjefferieshealthcarecon.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated June 1, 2023</a></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cybnjefferieshealthcarecon.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib6343ccf52aa489ca53655ebba921cc0_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.05pt;margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:120px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Cybin to Present at the Jefferies Healthcare Conference</font></div><div style="margin-top:4.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">TORONTO, CANADA </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8211; June 1, 2023 &#8211; </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> (NEO&#58;CYBN) (NYSE American&#58;CYBN) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cybin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin&#8217;s Chief Executive Officer, will present at the Jefferies Healthcare Conference taking place in New York City, NY from June 7-9, 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Mr. Drysdale&#8217;s presentation will be webcast live on Friday, June 9, 2023 at 8&#58;00 a.m. ET. To listen to the event, please </font><font style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">click here</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> to access the webcast. The archived webcast will also be available on the Company&#8217;s investor relations website on the </font><font style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Events &#38; Presentations</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> page.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Cybin</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin&#8217;s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.  For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on Twitter, LinkedIn, YouTube and Instagram.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Investor &#38; Media Contact&#58;&#160;</font></div><div style="padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gabriel Fahel</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Chief Legal Officer</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin Inc.</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1-866-292-4601</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">irteam&#64;cybin.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> &#8211; or &#8211; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">media&#64;cybin.com</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
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ML]F 1I&A9$"=;*->WUZ>I)]=ZW22",.#4(=DV&QP[C6TB%A,W"65<RL5P;S
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MII))7L'59&NK<Q1R?WV9_L& R/O^6;/1Z#A=5K:6W]/6]"0S!"R<7I)W&<C
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M*H$>MQY;7SE"V96(^!W>Q>QB.63%-?I$52Y4L;$@U[_AO:80/T5O:R"!B__
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M6EQ+?1$N2,<_EXR2)BKY-&XO3Y+G>VOY?7QMCC0G2;/B.I=A#^A30GK'3S\
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M;AA:''@"LW_3)\*BK:_OH2T$<30F3K;1J'LGGM&OBICB:S8+LS?E_NYZA[/
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M3M:QW-]=IR*NS2_CP;G7@=F_PPO_' 2^5\M%^#L$0:SD_P.!FI"CC7N0 P
*  !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
